about
The gut microbiome in human immunodeficiency virus infectionCo-infections and Pathogenesis of KSHV-Associated MalignanciesAdipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV InfectionConcentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV InfectionThe anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2Recent Insights into the HIV/AIDS Pandemic.Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Plasma IP-10 Concentrations Correlate Positively with Viraemia and Inversely with CD4 Counts in Untreated HIV InfectionMucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Immunity to HIV in Early LifeAssociation between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsDisentangling human tolerance and resistance against HIV.Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEK1/2-dependent upregulation of TNF-α and IL-6.Gut Microbiota Linked to Sexual Preference and HIV Infection.Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection.The tumor virus landscape of AIDS-related lymphomasPlasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count.[Factors associated with non-adherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala]Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy.HIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation.Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.Preservation affinity in consensus modules among stages of HIV-1 progression.Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyThe Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.Systemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their MothersCD38 Expression in a Subset of Memory T Cells Is Independent of Cell Cycling as a Correlate of HIV Disease Progression.IL-8 Alterations in HIV-1 Infected Children With Disease Progression.Activation Profile of Mycobacterium tuberculosis-Specific CD4(+) T Cells Reflects Disease Activity Irrespective of HIV StatusElevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections.Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainImpact of Depression and Inflammation on the Progression of HIV Disease.Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS PathogenesisIncreased stability and limited proliferation of CD4+ central memory T cells differentiate nonprogressive simian immunodeficiency virus (SIV) infection of sooty mangabeys from progressive SIV infection of rhesus macaques.T Cell Transcription Factors and Their Impact on HIV Expression.Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus.Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.Interplay between HIV-1 and Toll-like receptors in human myeloid cells: friend or foe in HIV-1 pathogenesis?Defensin gene variation and HIV/AIDS: a comprehensive perspective needed.Thymosin alpha 1 and HIV-1: recent advances and future perspectives.
P2860
Q26743543-9E2B5FBD-7A66-423D-B18D-546986C9D0E1Q26766493-922E38C5-5888-4FC0-93D3-4157D47C0B05Q27317216-719ECC84-4001-42B0-AE61-BDC96A8F4D38Q28468505-31EEC7FA-FD41-4986-A9A7-8E6FE74A7C8CQ28546013-E6080851-9BA8-4FA7-982C-7D173AF80A75Q30235024-27DB9DE2-59F6-4C57-990F-C49853AF6E77Q30362489-1D70B805-0F24-455E-A26D-7877B6DEE01BQ33668482-7C02EF6E-E8C2-4F28-977B-0A55DF224838Q33820903-E2338BD3-6A49-40F1-8131-06EAC521ECCEQ34033051-50658A5A-1B28-457F-96EC-28EE2F758869Q34057868-BC02BB9F-ED51-49B3-8ECD-2FF9C6267E4BQ34195511-3F4AC1ED-26CB-48F5-95F5-DA7228E3C642Q34199743-D82DB9D2-9258-4EA7-AFCD-4FB725674B45Q34676893-B6C47DEC-2F4C-4765-9A0E-17DC42C581ECQ35182200-FBB1BE7B-039C-49FA-8A89-5DC1BECE43B8Q35607311-CDBCC85B-819F-4A1D-BEB0-6B38B86B477AQ35858793-893411DB-C4BA-4326-9547-6996A7C6CC46Q35916350-CFB29043-E59E-4BA6-B757-65D6A5E15A69Q35945416-DC36DA08-5F44-4412-BE59-15AB8A3A2A18Q35970108-C2C3AE8C-43BD-48F1-BB5C-887FA9B9D5EBQ36238363-5CD44A42-6463-442F-8364-45CCE811A619Q36315350-782AA9F5-3488-4D0D-872E-32DE784119F8Q36360872-32815EE3-20FF-4ED9-A8AA-F7658FC20630Q36505647-843C5C65-7B2A-4BD9-929E-36C67A32C41EQ36516798-6FF7A631-C918-41BA-85B7-62CC5A4B855CQ36670411-FEABB444-DFE6-4CD6-B4D1-2CF856E2334EQ36731541-2262218F-5D01-4217-9AAF-9FE2B64D4DF4Q36992913-F28C7291-03AD-4D5F-8EAF-DE816F07C49CQ37013209-F7B32869-B785-460A-BE13-AAAF29948A5DQ37048079-DC5BFC31-0A05-4AD6-8F9D-1C8ED0D24E9FQ37098390-A2BD72A3-64DC-4953-8E35-8012CE49D2A2Q37138606-C49729F5-FAD8-4E78-A4C1-84AD97D3C104Q37174423-B35D92C9-3639-4998-A1EA-E2B95178A641Q37713913-4AD7D6A9-2925-4417-83CC-BC0CAF21F68AQ38179375-8B866C19-A388-4DD4-83C7-996ABFF26E58Q38182646-3008EC83-CB00-404B-B4E8-6ED82B6FA61EQ38530430-F54DF3FB-EB6F-4598-89FD-ED3F51F1AAC4Q38573911-4AA1F330-2DCB-4B92-A789-E8B58EC6CB86Q38766292-372DA5DB-D6BB-41B4-A2C7-D671063D2FD0Q38768132-EACF2877-0F43-46F6-AECE-70ABB0C4AB09
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HIV-associated chronic immune activation.
@ast
HIV-associated chronic immune activation.
@en
HIV-associated chronic immune activation.
@nl
type
label
HIV-associated chronic immune activation.
@ast
HIV-associated chronic immune activation.
@en
HIV-associated chronic immune activation.
@nl
prefLabel
HIV-associated chronic immune activation.
@ast
HIV-associated chronic immune activation.
@en
HIV-associated chronic immune activation.
@nl
P2860
P356
P1476
HIV-associated chronic immune activation.
@en
P2093
Mirko Paiardini
P2860
P304
P356
10.1111/IMR.12079
P577
2013-07-01T00:00:00Z